Alnylam and Regeneron to Collaborate on RNAi Therapeutics
- Posted by ISPE Boston
- On April 24, 2019
Alnylam and Regeneron have announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics with a focus on disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies’ scientific and technological expertise and […]
Read More